Superworth

Tvardi Therapeutics EPS TVRD

Diluted earnings per share by quarter and over the last twelve months, from 2013.

Last 12 months, to Jun 30, 2026
−$2.41
Latest quarter, Q2 FY26
−$0.69
Fiscal year 2025
−$5.71

Tvardi Therapeutics' earnings per share was −$2.41 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.69.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$5.71n/a
FY2024−$30.13n/a
FY2023−$78.48n/a
FY2022−$57.24n/a
FY2021−$62.28−2263%
FY2020$2.88n/a
FY2019−$89.64n/a
FY2018−$74.16n/a
FY2017−$68.76n/a
FY2016−$75.60n/a
FY2015−$36.00n/a
FY2014−$30.60n/a
FY2013−$61.56n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.69n/a−$2.41
Q1 FY26−$0.73n/a−$2.72
Q4 FY25−$0.40n/a−$5.71
Q3 FY25−$0.59n/a−$10.35
Q2 FY25−$1.00n/a−$11.90
Q1 FY25−$3.72n/a−$13.61
Q4 FY24−$5.04n/a−$30.13
Q3 FY24−$2.14n/a−$46.33
Q2 FY24−$2.71n/a−$62.91
Q1 FY24−$20.24n/a−$81.08
Q4 FY23−$21.24n/a−$78.48
Q3 FY23−$18.72n/a−$77.40

Against its peers

Companies in Drug Manufacturers - General nearest Tvardi Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
TVRDTvardi Therapeutics−$2.41
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Tvardi Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.